Uracil derivative as well as preparation method and application thereof
By developing a uracil compound to inhibit the lasB virulence factor of Pseudomonas aeruginosa, combined with traditional antibiotics, the treatment problem of multidrug-resistant Pseudomonas aeruginosa infection has been solved, significantly improving the antibacterial effect and demonstrating safety and efficient.
Patent Information
- Application Number
- CN202411122521.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-15
AI Technical Summary
The prior art is difficult to effectively treat multidrug-resistant Pseudomonas aeruginosa infection, especially due to the high pathogenicity of bacterial resistance and the virulence factor lasB, resulting in limited therapeutic effects of traditional antibiotics.
A uracil compound was developed to inhibit the virulence factor lasB regulated by its las population sensing system by selectively acting on Pseudomonas aeruginosa, and used in combination with antibiotics to enhance the antibacterial effect.
The uracil compound significantly inhibited the lasB activity of Pseudomonas aeruginosa, enhanced the antibacterial effects of ciprofloxacin and tobramycin, reduced bacterial infection, and showed safety and high efficiency in mouse models. .
Smart Images

Figure CN119019364A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine, and specifically relates to a method for preparing uracil derivatives and application of the uracil derivatives in preparing bacterial biofilm inhibitors. Background Art
[0002] Long-term use of antibiotics for antibacterial treatment has led to the widespread emergence of antibiotic resistance and "superbugs" worldwide. Currently, 7 million people die from microbial resistant infections each year worldwide, and bacterial resistance has become a major global public health threat. Pseudomonas aeruginosa is a widely used Gram-negative opportunistic pathogen associated with hospital infections. It is highly invasive and pathogenic. The emergence of bacterial resistance makes Pseudomonas aeruginosa infection difficult to treat. At the same time, the production of virulence factors such as elastase, exotoxins, and biofilms has aggravated the severity of Pseudomonas aeruginosa infection. Pseudomonas aeruginosa has been listed as one of the ESKAPE pathogens by the World Health Organization (WHO). Therefore, it is urgent to develop new treatment strategies for multidrug-resistant Pseudomonas aeruginosa. The production of virulence factors and the formation of biofilms are the main causes of the pathogenicity of Pseudomonas aeruginosa, which are regulated by the quorum sensing (QS) system. There are three main QS systems in Pseudomonas aeruginosa: las, rhl, and pqs. Among them, the las system occupies a core position. The signal molecule N-(3-oxododecanoyl)-L-homoserine lactone (3OC12-HSL) produced by it binds to the receptor protein LasR, which activates the expression of genes such as rhlI, rhlR, pqsR and pqsABCDE. LasR can directly regulate the production of virulence factors such as elastase lasB, alkaline protease and exotoxin, and regulate the production of rhamnolipids, pyocyanin and biofilm by regulating the rhl and pqs systems. Studies have shown that targeting lasB can reduce the pathogenicity of Pseudomonas aeruginosa. Therefore, the development of new regulated virulence factor lasB inhibitors is an effective strategy for treating Pseudomonas aeruginosa infections. Summary of the invention
[0003] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a uracil compound containing a structure shown in formula (I) and a preparation method and use thereof, wherein the compound can selectively act on Pseudomonas aeruginosa and inhibit the virulence factor lasB regulated by the las quorum sensing system of Pseudomonas aeruginosa.
[0004] In the first aspect of the present invention, there is provided a compound represented by formula (I) or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof:
[0005]
[0006] The second aspect of the present invention provides a pharmaceutical composition comprising the compound represented by formula (I), or at least one of its pharmaceutically acceptable salts, isomers, solvates or prodrugs, and optionally a pharmaceutically acceptable excipient or carrier.
[0007] The compound of the present invention, or its pharmaceutically acceptable salt, isomer, solvate or prodrug, or the pharmaceutical composition can be administered in a unit dosage form, and the administration route can be oral, intramuscular, subcutaneous, nasal, oral mucosa, skin, peritoneal or rectal. The dosage form can be tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, or freeze-dried powder injections. It can be a common preparation, a sustained-release preparation, a controlled-release preparation and various microparticle delivery systems.
[0008] Usually, the pharmaceutical composition of the present invention contains 0.1 to 99.9% by mass of the compound, or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof.
[0009] In some embodiments of the present invention, the administration form of the pharmaceutical composition comprises administering the compound, or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof, simultaneously, separately or sequentially with other active pharmaceutical ingredients.
[0010] The fourth aspect of the present invention provides a combination drug comprising a compound represented by formula (I) or at least one of its pharmaceutically acceptable salts, isomers, solvates or prodrugs, and an antibiotic.
[0011] Preferably, the antibiotics include ciprofloxacin and tobramycin.
[0012] Preferably, the mass ratio of the compound represented by formula (I) or its pharmaceutically acceptable salt, isomer, solvate or prodrug to the antibiotic is 1:0.5-10, preferably 1:2-3, more preferably 1:2-2.5.
[0013] In a fourth aspect, the present invention provides the use of the compound represented by the above formula (I) or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof, or the above pharmaceutical composition in the preparation of a bacterial lasB inhibitor.
[0014] Preferably, the bacterium is Pseudomonas aeruginosa.
[0015] The present invention also provides the use of the compound represented by the above formula (I) or its pharmaceutically acceptable salt, isomer, solvate or prodrug, or the above pharmaceutical composition in the preparation of antibacterial drugs.
[0016] Preferably, the bacteria is a bacterium, more preferably Pseudomonas aeruginosa.
[0017] The compounds represented by formula (I) of the present invention, especially compound (R)-6-(3-aminopyrrolidin-1-yl)-3-(benzo[d]thiazol-2-ylmethyl)-1-(but-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione, have excellent lasB inhibitory activity.
[0018] The uracil derivatives of formula (I) of the present invention have the chemical structure shown in Table 1:
[0019] Table 1 Structure and nomenclature of compounds
[0020]
[0021]
[0022]
[0023] The term "pharmaceutically acceptable salt" in the present application includes conventional salts formed with pharmaceutically acceptable inorganic or organic acids, or inorganic or organic bases.
[0024] "Pharmaceutical composition" includes a product containing a therapeutically effective amount of a compound of the invention, as well as any product resulting directly or indirectly from a combination of the compounds of the invention.
[0025] In a fourth aspect of the present invention, a method for preparing a uracil derivative represented by formula (I) is provided, which specifically comprises the following steps:
[0026] Route 1 includes the following steps:
[0027] (1.1) The raw material 6-chlorouracil 1 reacts with 1-bromo-2-butyne to obtain intermediate 2;
[0028] (1.2) Intermediate 2 is reacted with a bromine-substituted compound through alkylation to give intermediates 3a-3l;
[0029] (1.3) Intermediates 3a-3l react with (R)-3-aminopiperidine dihydrochloride to give final products 4a-4l;
[0030] The synthetic route at this time is:
[0031]
[0032] Route 2 includes the following steps:
[0033] (2.1) Intermediate 2 reacts with methyl 3-(bromomethyl)benzoate to generate intermediate 4;
[0034] (2.2) Intermediate 4 reacts with (R)-3-Boc-aminopiperidine to give intermediate 5;
[0035] (2.3) Intermediate 5 is further hydrolyzed to obtain intermediate 6;
[0036] (2.4) Intermediate 6 is reacted with different amino-substituted compounds 7a-7m to give intermediates 8a-8m;
[0037] (2.5) The intermediate 8a-8m is hydrolyzed to remove the Boc protecting group to obtain the target product 9a-9m;
[0038]
[0039] Route 3 includes the following steps:
[0040] (3.1) Add intermediate 2 to DMF solution, add sodium hydride and lithium bromide under ice bath condition, stir, add bromine-substituted compound to the reaction solution, and react at room temperature overnight; post-treatment: add water to the reaction solution to terminate the reaction, extract with ethyl acetate, combine the organic phases, wash with water, dry with anhydrous sodium sulfate, and purify by silica gel column chromatography to obtain intermediates 3r and 3p;
[0041] (3.2) Add intermediate 3r or 3p, substituted amine, sodium bicarbonate and activated molecular sieve (4A) to the ethanol solution, respectively, and react at 100°C for 2.5 hours; post-treatment: concentrate the reaction and purify by silica gel column chromatography to obtain the final products 10a-10f;
[0042]
[0043] The compound according to the embodiment of the present invention has at least the following beneficial effects:
[0044] (1) The present invention provides a uracil compound having a structure represented by formula (I), wherein compound 10e has excellent bacterial lasB inhibitory activity.
[0045] (2) The method for preparing the compound represented by formula (I) of the present invention has the advantages of short route, high yield, convenient post-treatment and good economy. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1The synergistic effect of compound 10e on CIP. (A) Bacterial plating results of the wound infection area of mice in the Control group, the compound alone group, the CIP alone group and the 10e-CIP combined group. Each experiment was repeated 3 times. (B) Monitoring of the wound area of mice, and the wound area was calculated using Image J. (C) Photographing and monitoring of the wound infection area of mice. (D) Bacterial survival rate in the wound infection area of mice. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (E) H&E stained slice images of the heart, liver, spleen, lung and kidney of mice in each group.
[0047] Figure 2 The synergistic effect of compound 10e on Tob. (A) Bacterial plating results of the wound infection area of mice in the Control group, the Tob alone administration group and the 10e-Tob combined administration group. Each experiment was repeated 3 times. (B) Monitoring of the wound area of mice, and the wound area was calculated using Image J. (C) Photographing and monitoring of the wound infection area of mice. (D) Bacterial survival rate in the wound infection area of mice. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (E) H&E stained slice images of the heart, liver, spleen, lung and kidney of mice in each group. DETAILED DESCRIPTION
[0048] The present invention is further described below in conjunction with specific implementation modes.
[0049] Example 1: Preparation of (R)-2-(4-(3-aminopiperidin-1-yl)-3-(but-2-yn-1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)acetonitrile (4a).
[0050] Add 6-chloropyrimidine-2,4(1H,3H)-dione (29.30g, 0.20mol) and N,N-diisopropylethylamine (DIPEA) (35.00ml, 0.30mol) to 50.00ml N,N-dimethylformamide (DMF) solution, stir at room temperature for 15min, then add 1-bromo-2-butyne (19.60ml, 0.22mol) to the reaction solution, stir and react overnight at room temperature. Post-treatment: Add a large amount of water to the reaction solution, precipitate a light yellow flocculent precipitate, filter the precipitate, wash with petroleum ether and dry, and the obtained light yellow powder is intermediate 2 (35.60g, yield 90%).
[0051] Add intermediate 2 (1.40 g, 7.00 mmol) to 10.00 ml DMF solution, add sodium hydride (NaH) (0.34 g, 14.00 mmol) and lithium bromide (LiBr) (1.80 g, 21.00 mmol) under ice bath conditions, and stir to react for 20 min. Then add different commercially available bromine-substituted compounds (10.50 mmol) to the reaction solution, and react overnight at room temperature. Post-treatment: Add water to the reaction solution to terminate the reaction, extract with ethyl acetate, combine the organic phases, wash with water, dry with anhydrous sodium sulfate for 2 h, and then purify by silica gel column chromatography to obtain crude intermediates 3a-3l (yield 60-95%).
[0052] To 20.0 ml of ethanol solution, intermediate 3a (2.50 mmol), (R)-3-aminopiperidine dihydrochloride (0.65 g, 3.75 mmol), sodium bicarbonate (1.05 g, 12.50 mmol) and 100.00 mg of activated molecular sieve (4A) were added respectively, and reacted at 100°C for 2.5 h. Post-treatment: The reaction was concentrated and purified by silica gel chromatography to collect product 4a as a white solid, with a yield of 57% and a purity of 95.98%. 1 H NMR (400 MHz, Chloroform-d 6 )δ5.24(s,1H),4.79(s,2H),4.54(t,J=2.4Hz,2H),3.38–3.31(m,1H),3.24(t,J=7.4Hz,1H),3.07–2.98(m,1H),2.78–2.68(m,1H), 2.57–2.48(m,1H),2.03–1.94(m,1H),1.92–1.85(m,1H),1.82(t,J=2.4Hz,3H),1.74–1.62(m,1H),1.55(s,2H),1.36–1.22(m,1H). 13 C NMR (100 MHz, Chloroform-d 6 )δ161.00,160.20,151.20,114.68,88.28,80.94,73.16,59.18,51.42,47.45,36.07,33.11,28.23,23.17,3.64.HRMS(ESI)m / z:calcd for C 15 H 20 N 5 O 2 + [M+H] + :302.1617,found:302.1622.
[0053] Example 2: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-(thiophen-3-ylmethyl)pyrimidine-2,4(1H,3H)-dione (4b).
[0054] Using intermediate 2, 3-(bromomethyl)thiophene and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4b was collected as a yellow solid with a yield of 60% and a purity of 95.00%. 1 H NMR (400 MHz, Chloroform-d 6 )δ7.40(s,1H),7.23(d,J=5.0Hz,1H),7.20(d,J=3.4Hz,1H),5.21(s,1H),5.07(s,2H), 4.53(q,J=2.4Hz,2H),3.31(d,J=11.7Hz,1H),3.19(d,J=12.0Hz,1H),3.01(tt,J=8.8, 4.0Hz,1H),2.68(t,J=11.2Hz,1H),2.48(t,J=10.2Hz,1H),2.05–1.94(m,2H),1.82(t, J=2.3Hz,3H),1.76(s,1H),1.65(dd,J=13.9,10.3Hz,1H),1.27(dt,J=14.3,8.4Hz,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ162.07,159.85,152.06,138.23,128.43,126.51,123.79,88.07(2C),75.08 ,59.12,51.24,47.66,39.28,35.93,33.24,23.39,3.55.HRMS(ESI)m / z:calcd for C 18 H 23 N 4 O 2 S + [M+H] + :359.1542,found:359.1557.
[0055] Example 3: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-(thiophen-2-ylmethyl)pyrimidine-2,4(1H,3H)-dione (4c).
[0056] Using intermediate 2, 2-(bromomethyl)thiophene and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4c was collected as a yellow solid with a yield of 40% and a purity of 95.01%. 1 H NMR (400 MHz, Chloroform-d 6 )δ7.23–7.19,6.95–6.91(m,1H),6.96(d,J=3.7Hz,1H),6.87(d,J=3.7Hz,1H),5. 23(s,1H),5.16(s,2H),4.55–4.52(m,2H),3.37–3.29(m,1H),3.22(d,J=11.8Hz, 1H),3.03(tt,J=8.6,3.8Hz,1H),2.72(d,J=11.5Hz,1H),2.50(s,1H),2.03–1.95 (m,1H),1.84(t,J=2.4Hz,3H),1.73–1.64(m,1H),1.54(s,2H),1.39–1.22(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ161.79,160.02,151.83,141.23,129.91,129.18,111.73,87.97,80.21,74.9 4,58.85,51.25,47.56,39.00,36.04,33.01,23.29,3.57.HRMS(ESI)m / z:calcd for C 18 H 23 N 4 O 2 S + [M+H] + :359.1542,found:359.1541.
[0057] Example 4: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((5-chlorothien-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (4d).
[0058] Using intermediate 2, 2-(bromomethyl)-5-chlorothiophene and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4d was collected as a yellow solid with a yield of 30% and a purity of 95.06%. 1 H NMR (400 MHz, Chloroform-d 6)δ6.99(d,J=3.7Hz,1H),6.74(d,J=3.7Hz,1H),5.24(s,1H),5.14(s,2H),4.55(d,J=1.3Hz,2H),3.34(d,J=11.6Hz,1H),3.23(d,J=12.0Hz, 1H),3.09–3.00(m,1H),2.72(t,J=11.0Hz,1H),2.52(s,1H),2.05–1.9 6(m,1H),1.85(t,J=2.3Hz,3H),1.65–1.59(m,2H),1.38–1.27(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ161.81,160.05,151.84,138.47,128.45,128.24,126.35,87.92,80.21,79.6 3,74.91,59.18,51.22,47.64,36.03,33.29,23.38,3.55.HRMS(ESI)m / z:calcd for C 18 H 22 N 4 O 2 SCl + [M+H] + :393.1152,found:393.1162.
[0059] Example 5: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-(thiazol-4-ylmethyl)pyrimidine-2,4(1H,3H)-dione (4e).
[0060] Using intermediate 2, 4-(bromomethyl)thiazole and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4d was collected as a white solid with a yield of 50% and a purity of 95.12%. 1 H NMR (400 MHz, Chloroform-d 6)δ8.73(s,1H),7.29(s,1H),5.29(s,2H),5.26(s,1H),4.57–4.51(m,2H ),3.33(d,J=9.9Hz,1H),3.21(d,J=12.0Hz,1H),3.02(tt,J=8.7,3.9Hz, 1H),2.70(t,J=10.9Hz,1H),2.50(t,J=10.2Hz,1H),2.02–1.93(m,1H),1 .90–1.83(m,1H),1.81(t,J=2.0Hz,3H),1.69(s,2H),1.37–1.22(m,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ162.59,159.46,152.66,152.60,152.16,116.31,89.18,80.20,73.75,5 9.31,51.45,47.53,40.29,35.57,33.16,23.24,3.67.HRMS(ESI)m / z:calcd for C 17 H 22 N 5 O 2 S + [M+H] + :360.1494,found:360.1505.
[0061] Example 6: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((2-chlorothiazol-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione (4f).
[0062] Using intermediate 2, 4-(bromomethyl)-2-chlorothiazole and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4f was collected as a yellow solid with a yield of 51% and a purity of 96.94%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.63(s,1H),5.24(s,1H),5.17(s,2H),4.54(d,J=1.9Hz,2H),3.34(d,J=9.8Hz,1H),3.23(d,J=12.1Hz,1H),3.04(tt,J=8.7,3.9Hz,1H), 2.72(t,J=11.3Hz,1H),2.52(t,J=10.5Hz,1H),2.04–1.95(m,1H),1.84(t,J=1.9Hz,3H),1.75–1.63(m,1H),1.58(s,2H),1.38–1.24(m,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ162.11,159.75,152.56,151.76,141.90,134.79,88.77,80.58,73.42,5 9.22,51.38,47.48,36.39,35.78,33.13,23.20,3.66.HRMS(ESI)m / z:calcd for C 17 H 21 N 5 O 2 SCl + [M+H] + :394.1104,found:394.1105.
[0063] Example 7: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((2-methylthiazol-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione (4 g).
[0064] Using intermediate 2, 4-(bromomethyl)-2-methylthiazole and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4g was collected as a yellow solid with a yield of 44% and a purity of 95.19%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.00(s,1H),5.28(s,1H),5.22(s,2H),4.56(d,J=2.4Hz,2H),3.36(d, J=11.6Hz,1H),3.24(d,J=11.3Hz,1H),3.10–3.02(m,1H),2.75(d,J=11.1 Hz,1H),2.68(s,3H),2.53(d,J=10.6Hz,1H),2.05–1.97(m,1H),1.94–1.8 6(m,1H),1.83(t,J=2.3Hz,3H),1.74(d,J=3.7Hz,2H),1.39–1.27(m,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ165.48,162.41,159.39,152.00,151.24,115.18,88.92,80.02,73.77,59.1 2,51.34,47.39,40.47,35.50,33.04,23.12,19.00,3.52.HRMS(ESI)m / z:calcd for C 18 H 24 N 5 O 2 S + [M+H] + :374.1651,found:374.1664.
[0065] Example 8: Preparation of (R)-methyl 5-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn-1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)furan-2-carboxylate (4h).
[0066] Using intermediate 2, 5-(bromomethyl)-2-furoic acid methyl ester and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4h was collected as a white solid with a yield of 61% and a purity of 95.96%. 1 H NMR (400 MHz, DMSO-d 6 )δ7.23(s,1H),6.45(s,1H),5.20(d,J=4.0Hz,1H),5.00(s,2H),4.48(s,2H),3.84–3.65(m,3H),2.88–2.6 4(m,3H),2.51(s,2H),1.76(d,J=16.8Hz,5H),1.56(d,J=12.8Hz,2H),1.24(dq,J=38.0,13.6,12.4Hz,2H).13 C NMR (100 MHz, Chloroform-d 6 )δ162.19,159.60,159.05,154.68,151.88,143.55,119.04,110.59,88.90,80.38,7 3.57,59.10,51.78,51.44,47.47,37.51,35.70,33.01,23.19,3.62.HRMS(ESI)m / z:C 20 H 25 N 4 O 5 [M+H] + =401.1825, found[M+H] + =401.1843.
[0067] Example 9: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((3,5-dimethylisoxazol-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione (4i).
[0068] Using intermediate 2, 4-(bromomethyl)-3,5-dimethylisoxazole and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4i was collected as a white solid with a yield of 65% and a purity of 95.65%. 1 H NMR (400 MHz, Chloroform-d 6 )δ5.17(s,1H),4.82(s,2H),4.50(q,J=2.5Hz,2H),3.29(d,J=15.7Hz,1 H),3.18(d,J=11.7Hz,1H),3.00(tt,J=8.7,3.8Hz,1H),2.68(t,J=11.1H z,1H),2.46(s,4H),2.28(s,3H),2.01–1.92(m,1H),1.89–1.81(m,1H),1 .79(t,J=4.7Hz,3H),1.73–1.61(m,1H),1.49(s,2H),1.34–1.18(m,1H). 13 C NMR (100 MHz, Chloroform-d 6)δ168.75,162.58,160.11,159.44,152.01,110.01,88.93,80.33,73.65,59.33,5 1.45,47.50,35.51,33.19,33.01,23.19,11.56,10.66,3.62.HRMS(ESI)m / z:calcd forC 19 H 26 N 5 O 3 + [M+H] + :372.2036,found:372.2066.
[0069] Example 10: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)pyrimidine-2,4(1H,3H)-dione (4j).
[0070] Using intermediate 2, 5-(bromomethyl)-1,3-dimethyl-1H-pyrazole and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4j was collected as a white solid with a yield of 58% and a purity of 96.35%. 1 H NMR (400 MHz, Chloroform-d 6 )δ6.06(s,1H),5.14(s,1H),4.97(s,2H),4.52–4.38(m,2H),3.87(s,3H),3. 25(d,J=13.3Hz,1H),3.14(d,J=11.5Hz,1H),2.98–2.90(m,1H),2.62(t,J=10 .9Hz,1H),2.47–2.37(m,1H),2.10(s,3H),1.94–1.87(m,1H),1.84–1.77(m,1 H),1.75(t,J=4.7Hz,3H),1.66–1.56(m,1H),1.49(s,2H),1.28–1.12(m,1H). 13 C NMR (100 MHz, Chloroform-d 6 )δ162.23,159.47,151.90,147.06,138.47,106.93,88.87,80.33,73.58,59.24,51. 38,47.46,36.53,35.59,34.78,33.13,23.17,13.33,3.62.HRMS(ESI)m / z:calcdfor C 19 H27 N 6 O 2 + [M+H] + :371.2195,found:371.2207.
[0071] Example 11: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (4k).
[0072] Using intermediate 2, 2-(bromomethyl)-5-methyl-1,3,4-oxadiazole and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 4k was collected as a white solid with a yield of 62% and a purity of 96.50%. 1 H NMR (400 MHz, Chloroform-d 6 )δ5.28(s,2H),5.27(s,1H),4.60–4.50(m,2H),3.37(d,J=13.1Hz,1H), 3.26(d,J=11.6Hz,1H),3.08–2.97(m,1H),2.75(t,J=10.9Hz,1H),2.55 (d,J=10.5Hz,1H),2.49(s,3H),2.04–1.96(m,1H),1.93–1.85(m,1H),1 .82(t,J=4.7Hz,3H),1.75–1.65(m,1H),1.54(s,1H),1.38–1.19(m,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ163.94,162.26,161.92,159.92,151.83,88.72,80.58,73.45,59.24,51 .45,47.53,35.90,35.52,33.10,23.24,11.00,3.67.HRMS(ESI)m / z:calcd for C 17 H 23 N 6 O 3 + [M+H] + :359.1832,found:359.1854.
[0073] Example 12: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-(4-methylbenzyl)pyrimidine-2,4(1H,3H)-dione (41).
[0074] Using intermediate 2, 1-(bromomethyl)-4-toluene and (R)-3-aminopiperidine dihydrochloride as raw materials, the synthesis method was the same as compound 4a, and the product 41 was collected as a white solid with a yield of 57% and a purity of 95.07%. 1 H NMR (400 MHz, Chloroform-d 6 )δ7.44(d,J=8.1Hz,2H),7.12(d,J=7.8Hz,2H),5.24(s,1H),5.07(s,2H),4.53( q,J=2.4Hz,2H),3.32(d,J=11.8Hz,1H),3.21(d,J=11.9Hz,1H),3.07–2.99(m,1H ),2.70(s,1H),2.49(s,1H),2.32(s,3H),1.99(q,J=5.6,4.9Hz,1H),1.91–1.86( m,1H),1.83(t,J=2.3Hz,3H),1.75–1.64(m,1H),1.50(s,2H),1.33–1.27(m,1H). 13 C NMR (100 MHz, Chloroform-d 6 )δ162.88,159.28,152.21,137.06,134.15,129.18,129.18,128.91,128.91,89.15,80.10, 73.84,59.24,51.42,47.49,43.95,35.46,33.13,23.23,21.10,3.62.HRMS(ESI)m / z:calcd for C 21 H 27 N 4 O 2 + [M+H] + :367.2134,found:367.2148.
[0075] Example 13: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn-1-yl)-2,6-dioxapyrimidin-1(2H)-yl)methyl)-N-(pyridin-3-ylmethyl)benzamide (9a).
[0076] Add intermediate 2 (10.00 g, 0.05 mol) to 25 ml DMF solution, add sodium hydride (NaH) (2.40 g, 0.10 mol) and lithium bromide (LiBr) (13.00 g, 0.15 mol) under ice bath conditions, and stir to react for 20 min. Then add 3-bromomethylbenzoic acid methyl ester (13.70 g, 0.06 mol) to the reaction solution, and react overnight at room temperature. Post-treatment: add water to the reaction solution to terminate the reaction, extract with ethyl acetate, combine the organic phases, wash with water, dry with anhydrous sodium sulfate for 2 h, and then purify by silica gel column chromatography to obtain intermediate 4 (PE: EA = 6: 1). Add intermediate 4 (13.90 g, 0.04 mol), (R)-3-Boc-aminopiperidine (9.60 g, 0.05 mol), sodium bicarbonate (16.80 g, 0.20 mol) and 3.00 g activated molecular sieve (4A) to 50 ml ethanol solution, and react at 100 ° C for 4 hours. Post-treatment: After the reaction is concentrated, it is purified by silica gel chromatography to obtain intermediate 5 (PE: EA = 3: 1). Add intermediate 5 (18.00 g, 0.04 mol) to 15 ml methanol to dissolve, slowly add NaOH solution (1 M) to the reaction solution while stirring, and react at room temperature for 10 hours. Post-treatment: After the hydrolysis is complete, slowly add dilute hydrochloric acid (1 M) to the reaction solution, and white solids are precipitated continuously. Adjust the pH to 3-4. Filter and the obtained white solid is intermediate 6. Add intermediate 6 (0.30 g, 0.60 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.170 g, 0.90 mmol), 1-hydroxybenzotriazole (HOBT) (0.12 g, 0.90 mmol) and DIPEA (0.3 ml, 1.80 mmol) to 10 ml of dichloromethane solution, stir and react for 15 min, then add commercially available compound 7a, 3-aminomethylpyridine (0.60 mmol), and react at room temperature overnight. Post-treatment: The reaction was concentrated and purified by silica gel chromatography to obtain intermediate 8a. Dissolve intermediate 8a in 8 ml of dichloromethane solution, slowly add trifluoroacetic acid (8 ml, TFA) dropwise under ice bath, and react at room temperature for 2-4 h. Post-treatment: Add saturated NaHCO to the reaction solution. 3 The solution was adjusted to a weak alkaline pH of 7-8, the reaction solution was extracted with dichloromethane, the organic phases were combined, washed with saturated brine for 3-4 times, and then dried over anhydrous sodium sulfate for 2 h. The liquid was concentrated to obtain the final product 9a, which was collected as a white solid with a yield of 29% and a purity of 96.14%. 1 H NMR (400 MHz, Chloroform-d 6)δ8.60(d,J=1.7Hz,1H),8.52(dd,J=4.7,1.7Hz,1H),7.86(s,1H),7.78(d,J=7.8Hz,1H),7.73(d,J=7.8Hz, 1H),7.67(d,J=7.8Hz,1H),7.38(t,J=7.7Hz,1H),7.27(t,J=4.8,0.8Hz,1H),7.03(t,J=5.3Hz,1H),5.23(s ,1H),5.11(s,2H),4.64(d,J=5.9Hz,2H),4.50(q,J=2.4Hz,2H),3.37–3.29(m,1H),3.28–3.20(m,1H),3.12 (s,1H),2.77(s,1H),2.61(s,1H),2.06(s,3H),1.82(t,J=2.3Hz,3H),1.73–1.64(m,1H),1.40–1.28(m,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ167.44,162.90,159.50,152.24,149.25,148.80,137.46,135.79,134.20,134.15,132.77,128.82,127.25,127.0 1,123.60,89.04,80.41,73.62,58.98,51.46,47.50,44.09,41.44,35.69,32.91,23.18,3.61.HRMS(ESI)m / z:calcd forC 27 H 31 N 6 O 3 + [M+H] + :487.2458,found:487.2467.
[0077] Example 14: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn-1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(thiophen-2-ylmethyl)benzamide (9b).
[0078] Commercially available compound 7b, 2-aminomethylthiophene, was used as the raw material. The synthesis method was the same as compound 9a. The product 9b was collected as a yellow solid with a yield of 26% and a purity of 95.10%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.84(s,1H),7.77(d,J=7.7Hz,1H),7.66(d,J=7.7Hz,1H),7.38(t,J=7.7Hz,1H),7.24(d,J=5.1Hz,1H),7.0 5(d,J=3.4Hz,1H),6.97(t,J=4.3Hz,1H),6.71(t,J=5.6Hz,1H),5.25(s,1H),5.12(s,2H),4.81(d,J=5.6Hz,2H ),4.52(s,2H),3.35(d,J=11.6Hz,1H),3.24(d,J=11.8Hz,1H),3.06(dd,J=8.9,4.9Hz,1H),2.79–2.68(m,1H), 2.56(s,1H),2.08(s,2H),1.93–1.86(m,1H),1.82(t,J=1.8Hz,3H),1.75–1.63(m,1H),1.29(d,J=12.3Hz,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ167.01,162.90,159.43,152.22,140.91,137.46,134.26,132.68,128.78,127.23,126.91,126.89,126.23,1 25.28,89.11,80.41,73.64,51.49,47.51,44.09,38.76,35.70,32.72,29.71,23.22,3.68.HRMS(ESI)m / z:calcd for C 26 H 30 N 5 O 3 S + [M+H] + :492.2069,found:492.2088.
[0079] Example 15: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn-1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-isopropylbenzamide (9c).
[0080] Commercially available compound 7c, i.e., isopropylamine, was used as the raw material. The synthesis method was the same as compound 9a. The product 9c was collected as a white solid with a yield of 19% and a purity of 96.61%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.80(s,1H),7.72(d,J=6.2Hz,1H),7.64(d,J=7.7Hz,1H),7.37(t,J=8.3Hz,1H),6.05(d, J=8.0Hz,1H),5.26(s,1H),5.13(s,2H),4.53(t,J=2.2Hz,2H),4.33–4.23(m,1H),3.41–3.3 3(m,1H),3.25(d,J=11.3Hz,1H),3.12–3.04(m,1H),2.75(s,1H),2.57(s,1H),2.07–1.98(m ,1H),1.89(d,J=4.4Hz,1H),1.83(t,J=2.3Hz,3H),1.40(d,J=3.5Hz,1H),1.32–1.25(m,9H). 13 C NMR (100 MHz, DMSO-d 6 )δ165.77,162.29,159.92,152.24,137.97,135.44,130.43,128.56,127.30,126.25,87.98,80.15,75 .01,59.04,51.24,47.65,43.80,41.45,36.05,33.16,23.37,22.78,22.78,3.54.HRMS(ESI)m / z:calcd for C 24 H 32 N 5 O 3 + [M+H] + :438.2505,found:438.2512.
[0081] Example 16: Preparation of (R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-(3-(pyrrolidine-1-carbonyl)benzyl)pyrimidine-2,4(1H,3H)-dione (9d).
[0082] The commercially available compound 7d, i.e., tetrahydropyrrole, was used as the raw material. The synthesis method was the same as that of compound 9a. The product 9d was collected as a white solid with a yield of 26% and a purity of 95.93%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.52(d,J=7.3Hz,2H),7.38–7.30(m,2H),5.23(s,1H),5.08(s,2H),4.50(q,J=2.4Hz,2H),3.57(t,J=6.9Hz,2H),3.48(s,4H),3.44–3.3 7(m,2H),3.30(s,2H),2.91(s,2H),2.04(s,1H),1.94(q,J=6.5Hz,2H),1.86(t,J=6.6Hz,2H),1.80(s,3H),1.68(s,1H),1.40–1.21(m,1H). 13 C NMR (100 MHz, DMSO-d 6 )δ168.43,162.25,159.52,152.07,137.78,137.59,129.58,128.66,126.90,126.33,88.85,80.21,74.95 ,53.02,51.80,49.38,46.53,46.38,43.82,36.03,36.01,27.84,26.42,24.35,3.55.HRMS(ESI)m / z:calcd for C 25 H 32 N 5 O 3 + [M+H] + :450.2505,found:450.2504.
[0083] Example 17: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn-1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-cyclohexylbenzamide (9e).
[0084] The commercially available compound 7e, i.e. cyclohexylamine, was used as the raw material. The synthesis method was the same as that of compound 9a. The product 9e was collected as a white solid with a yield of 32% and a purity of 96.22%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.80(s,1H),7.71(d,J=7.8Hz,1H),7.62(d,J=7.8Hz,1H),7.36(t,J=7.7Hz,1H),6.14(d,J=8.1Hz,1H),5.26(s ,1H),5.12(s,2H),4.52(q,J=2.4Hz,2H),4.01–3.91(m,1H),3.34(d,J=11.5Hz,1H),3.23(d,J=12.1Hz,1H),3.11 –3.02(m,1H),2.74(t,J=10.9Hz,1H),2.57(d,J=10.3Hz,1H),2.45(s,3H),2.03(d,J=6.4Hz,2H),1.89(dt,J=13. 6,4.1Hz,1H),1.83(t,J=4.6Hz,3H),1.79–1.74(m,2H),1.72–1.63(m,2H),1.44–1.36(m,2H),1.31–1.19(m,4H). 13 C NMR (100 MHz, DMSO-d 6 )δ165.80,162.30,159.91,152.24,137.95,135.49,130.41,128.56,127.34,126.31,88.00,80.15,79.63,75. 00,58.87,51.25,48.82,47.61,43.80,36.04,32.86(2C),30.14,25.73,25.41(2C),3.54.HRMS(ESI)m / z:calcd for C 27 H 36 N 5 O 3 + [M+H] + :478.2818,found:478.2831.
[0085] Example 18: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(cyclohexylmethyl)benzamide (9f).
[0086] The commercially available compound 7f, cyclohexylmethylamine, was used as the raw material. The synthesis method was the same as that of compound 9a. The product 9f was collected as a white solid with a yield of 30% and a purity of 97.59%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.82(s,1H),7.73(d,J=7.9Hz,1H),7.64(d,J=7.7Hz,1H),7.37(t,J=7.7Hz,1H),6.40(t,J=6.0Hz,1H),5.25(s ,1H),5.12(s,2H),4.52(q,J=2.4Hz,2H),3.34(d,J=11.4Hz,1H),3.28(t,J=6.5Hz,2H),3.23(d,J=11.8Hz,1H),3 .07–2.98(m,1H),2.72(t,J=10.4Hz,1H),2.52(t,J=10.3Hz,1H),2.04–1.95(m,1H),1.92–1.85(m,1H),1.83(t,J =2.3Hz,3H),1.75(d,J=11.6Hz,7H),1.70–1.65(m,2H),1.62–1.54(m,1H),1.29–1.21(m,3H),1.06–0.93(m,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ167.47,162.88,159.46,152.26,137.37,135.06,132.23,128.69,127.09,126.72,89.12,80.35,73.68,59.27, 51.46,47.54,46.27,44.10,38.03,35.65,33.11,30.95(2C)26.42,25.84(2C),23.23,3.64.HRMS(ESI)m / z:calcd forC 28 H 38 N 5 O 3 + [M+H] + :492.2975,found:492.2970.
[0087] Example 19: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(2-cyclohexylethyl)benzamide (9 g).
[0088] Commercially available compound 7g, 2-cyclohexylethylamine, was used as the raw material. The synthesis method was the same as compound 9a. The product 9g was collected as a white solid with a yield of 45% and a purity of 95.53%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.81(s,1H),7.74(d,J=7.8Hz,1H),7.65(d,J=7.6Hz,1H),7.37(t,J=7.7Hz,1H),6.25(s,1H),5.2 6(s,1H),5.13(s,2H),4.53(t,J=2.4Hz,2H),3.50–3.43(m,2H),3.35(d,J=11.5Hz,1H),3.23(d,J=1 1.7Hz,1H),3.06(s,1H),2.74(s,1H),2.54(s,1H),2.21(s,2H),2.01(d,J=22.3Hz,2H),1.83(t,J=2 .5Hz,3H),1.77–1.68(m,4H),1.52(q,J=7.2Hz,2H),1.36–1.14(m,7H),0.98(td,J=12.0,2.9Hz,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ167.35,162.91,159.44,152.23,137.33,135.00,132.34,128.73,127.08,126.79,89.15,80.40,73.65,59.03,51. 48,47.46,44.11,37.97,37.12,35.65,35.49,33.20(2C),32.90,26.53,26.23(2C),23.19,3.68.HRMS(ESI)m / z:calcd for C 29 H 40 N 5 O 3 + [M+H] + :506.3131,found:506.3145.
[0089] Example 20: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(3-fluorophenethyl)benzamide (9h).
[0090] Commercially available compound 7h, 2-(3-fluorophenyl)ethan-1-amine, was used as the raw material. The synthesis method was the same as compound 9a. The product 9h was collected as a white solid with a yield of 39% and a purity of 95.04%. 1 H NMR (400 MHz, Chloroform-d 6)δ7.79(s,1H),7.71(d,J=7.8Hz,1H),7.66(d,J=7.8Hz,1H),7.38(t,J=7.7Hz,1H),7.34–7.29(m,1H),7.04(d,J=7 .7Hz,1H),6.99–6.92(m,2H),6.38(t,J=5.6Hz,1H),5.25(s,1H),5.12(s,2H),4.53(q,J=2.4Hz,2H),3.70(q,J=7. 0Hz,2H),3.35(d,J=11.6Hz,1H),3.24(d,J=11.1Hz,1H),3.10–3.01(m,1H),2.95(t,J=7.1Hz,2H),2.75(d,J=11.5 Hz,1H),2.53(s,1H),2.04–1.97(m,1H),1.89(s,2H),1.83(t,J=2.3Hz,3H),1.75–1.64(m,1H),1.35–1.29(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ166.50,162.26,159.66,157.71,152.14,137.96,135.29,130.65,130.50,128.63,128.04,127.72,127.14,126.15,120. 74,111.13,88.52,79.66,74.97,55.72,55.34,51.60,46.96,43.88,36.01,30.28,29.87,22.37,3.55.HRMS(ESI)m / z:calcd for C 29 H 33 N 5 O 3 F + [M+H] + :518.2567,found:518.2582.
[0091] Example 21: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(3-chlorophenethyl)benzamide (9i).
[0092] Commercially available compound 7i, 2-(3-chlorophenyl)ethan-1-amine, was used as the raw material. The synthesis method was the same as compound 9a. The product 9i was collected as a white solid with a yield of 32% and a purity of 96.88%. 1H NMR (400 MHz, Chloroform-d 6 )δ7.79(s,1H),7.70(d,J=7.9Hz,1H),7.64(d,J=6.9Hz,1H),7.36(t,J=7.7Hz,1H),7.28(s,1H),7.25–7.20(m,2H),7 .14(d,J=7.4Hz,1H),6.53(t,J=5.9Hz,1H),5.24(s,1H),5.10(s,2H),4.51(q,J=2.5Hz,2H),3.67(q,J=6.8Hz,2H),3 .34(d,J=10.2Hz,1H),3.23(d,J=10.8Hz,1H),3.11–3.02(m,1H),2.91(t,J=7.2Hz,2H),2.75(d,J=11.0Hz,1H),2.61 –2.50(m,1H),1.99(d,J=8.9Hz,2H),1.93–1.85(m,1H),1.82(t,J=2.3Hz,3H),1.75–1.61(m,1H),1.39–1.27(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ166.65,162.27,159.91,152.24,142.64,138.09,135.18,133.37,130.71,130.59,129.02,128.67,127.96,127.16,126. 56,126.11,88.00,80.15,75.02,58.99,51.25,47.64,43.80,36.05,35.01,33.11,23.34,21.86,3.55.HRMS(ESI)m / z:calcd for C 29 H 33 N 5 O 3 Cl + [M+H] + :534.2272,found:534.2281.
[0093] Example 22: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(3-bromophenethyl)benzamide (9j).
[0094] Commercially available compound 7j, 2-(3-bromophenyl)ethan-1-amine, was used as the raw material. The synthesis method was the same as compound 9a. The product 9j was collected as a yellow solid with a yield of 32% and a purity of 95.04%. 1 H NMR (400 MHz, DMSO-d 6 )δ8.57(t,J=5.5Hz,1H),7.73(s,1H),7.66(d,J=5.9Hz,1H),7.46(s,1H),7.39(d,J=6.3Hz,3H),7.25(d ,J=6.4Hz,2H),5.21(s,1H),4.98(s,2H),4.49(q,J=2.6Hz,2H),3.48(q,J=6.7Hz,2H),3.23(dd,J=11.7 ,3.5Hz,1H),3.16(d,J=11.9Hz,1H),2.85(t,J=7.1Hz,3H),2.71(t,J=11.0Hz,1H),2.45(d,J=10.2Hz,1 H),1.84(d,J=9.0Hz,2H),1.77(t,J=2.4Hz,3H),1.75(s,1H),1.63–1.51(m,1H),1.21(d,J=12.6Hz,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ166.68,162.28,159.89,152.24,142.93,138.08,135.19,131.91,130.90,130.73,129.44,128.67,128.33,127.18,126. 13,122.09,88.04,80.16,75.02,58.74,51.28,47.57,43.82,40.99,36.05,34.98,32.89,23.29,3.55.HRMS(ESI)m / z:calcd for C 29 H 33 N 5 O 3 Br + [M+H] + :578.1767,found:578.1774.
[0095] Example 23: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(3-methylphenethyl)benzamide (9k).
[0096] Commercially available compound 7k, 2-(3-methylphenyl)ethan-1-amine, was used as the raw material. The synthesis method was the same as compound 9a. The product 9k was collected as a white solid with a yield of 52% and a purity of 95.14%. 1 H NMR (400 MHz, Chloroform-d 6 )δ7.79(s,1H),7.68(d,J=7.7Hz,1H),7.64(d,J=7.8Hz,1H),7.36(t,J=7.7Hz,1H),7.23(t,J=7.4Hz,1H),7.10–7.06(m, 2H),7.05(d,J=1.9Hz,1H),6.49(t,J=5.7Hz,1H),5.25(s,1H),5.11(s,2H),4.52(q,J=2.4Hz,2H),3.68(q,J=6.8Hz,2H), 3.34(d,J=8.7Hz,1H),3.22(d,J=11.4Hz,1H),3.09–3.01(m,1H),2.90(t,J=7.2Hz,2H),2.79–2.67(m,1H),2.60–2.48(m, 1H),2.36(s,3H),2.01(d,J=12.3Hz,2H),1.92–1.85(m,1H),1.83(t,J=2.4Hz,3H),1.75–1.64(m,1H),1.33–1.27(m,2H). 13 C NMR (100 MHz, Chloroform-d 6 )δ167.45,162.90,159.47,152.23,138.95,138.28,137.35,134.86,132.35,129.64,128.68,128.55,127.24,126.65,125.84, 89.17,80.40,73.66,59.02,51.50,47.45,44.11,41.33,35.70,32.95,31.50,29.68,23.15,21.36,3.61.HRMS(ESI)m / z:calcd for C 30 H 36 N 5 O 3 + [M+H] + :514.2818,found:514.2812.
[0097] Example 24: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(2-fluorophenethyl)benzamide (91).
[0098] Commercially available compound 71, 2-(2-fluorophenyl)ethan-1-amine, was used as the raw material. The synthesis method was the same as compound 9a. The product 91 was collected as a white solid with a yield of 52% and a purity of 95.08%. 1 H NMR (400 MHz, Chloroform-d 6 )δ7.78(s,1H),7.67(d,J=7.8Hz,1H),7.62(d,J=7.6Hz,1H),7.34(t,J=7.7Hz,1H),7.23(ddd,J=14.0,7.9,5.7Hz ,2H),7.12–7.00(m,2H),6.66(t,J=5.8Hz,1H),5.24(s,1H),5.09(s,2H),4.55–4.48(m,2H),3.67(q,J=6.6Hz,2H ),3.33(d,J=11.5Hz,1H),3.23(d,J=12.1Hz,1H),3.11–3.02(m,1H),2.97(t,J=7.1Hz,2H),2.70(s,2H),2.56(t, J=10.3Hz,1H),2.02–1.96(m,1H),1.92–1.85(m,1H),1.81(t,J=4.7Hz,3H),1.74–1.62(m,1H),1.36–1.27(m,2H). 13 CNMR (100MHz, DMSO-d 6 )δ166.63,162.29,159.90,152.24,138.07,135.17,131.69,130.71,128.67,127.11,126.61,126.45,126.12,124.84,115.68 ,115.47,88.02,80.16,79.63,75.00,58.80,51.27,47.59,43.81,36.05,32.95,29.02,23.30,3.54.HRMS(ESI)m / z:calcdfor C 29 H 33 N 5 O 3 F + [M+H] + :518.2567,found:518.2570.
[0099] Example 25: Preparation of (R)-3-((4-(3-aminopiperidin-1-yl)-3-(but-2-yn--1-yl)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)methyl)-N-(2-chlorophenethyl)benzamide (9m).
[0100] Commercially available compound 7m, 2-(2-chlorophenyl)ethan-1-amine, was used as the raw material. The synthesis method was the same as compound 9a. The product 9m was collected as a white solid with a yield of 26% and a purity of 95.87%. 1 H NMR (400 MHz, Chloroform-d 6 )δ7.79(s,1H),7.71(d,J=7.7Hz,1H),7.64(d,J=7.6Hz,1H),7.40–7.34(m,2H),7.29–7.27(m,1H ),7.27–7.17(m,2H),6.51(t,J=5.9Hz,1H),5.25(s,1H),5.11(s,2H),4.52(d,J=2.8Hz,2H),3.7 1(q,J=6.7Hz,2H),3.34(d,J=11.4Hz,1H),3.23(d,J=11.9Hz,1H),3.08(q,J=9.4,8.2Hz,3H),2. 74(s,1H),2.50(s,3H),2.02(s,1H),1.82(t,J=2.6Hz,3H),1.74–1.65(m,1H),1.37–1.26(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ166.67,162.30,159.91,152.23,138.06,137.34,135.15,133.60,131.61,130.72,129.70,128.67,128.65,127.72,127. 11,126.15,88.00,80.17,75.00,58.82,51.26,47.59,43.81,39.31,36.06,33.29,32.96,23.31,3.54.HRMS(ESI)m / z:calcd for C 29 H 33 N 5 O 3 Cl + [M+H] + :534.2272,found:534.2270.
[0101] Example 26: Preparation of (R)-6-(3-aminopyrrolidin-1-yl)-1-(but-2-yn-1-yl)-3-((2-oxo-1,2-dihydroquinolin-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10a).
[0102] Add intermediate 2 (5.00 g, 0.03 mol) to 15 ml DMF solution, add sodium hydride (NaH) (1.20 g, 0.05 mol) and lithium bromide (LiBr) (6.50 g, 0.075 mol) under ice bath conditions, and stir to react for 15 min. Then add commercially available compounds 4-(bromomethyl)quinolin-2(1H)-one and 2-(bromomethyl)benzothiazole (0.030 mol) to the reaction solution, respectively, and react at room temperature overnight. Post-treatment: Add water to the reaction solution to terminate the reaction, extract with ethyl acetate, combine the organic phases, wash with water, dry with anhydrous sodium sulfate for 2 h, and purify by silica gel column chromatography to obtain intermediates 3r and 3p.
[0103] To 10 ml of ethanol solution, add intermediate 3r (2.50 mmol), (R)-1-bromopyrrolidin-3-amine (3.750 mmol), sodium bicarbonate (1.05 g, 12.50 mmol) and 100.00 mg of activated molecular sieve (4A) respectively, and react at 100 ° C for 2.5 h. Post-treatment: The reaction was concentrated and purified by silica gel chromatography to obtain the final product 10a. The product 10a was collected as a white solid with a yield of 43% and a purity of 95.11%. 1 H NMR (400 MHz, DMSO-d 6 )δ11.50(s,1H),7.89(d,J=8.1Hz,1H),7.55(t,J=7.7Hz,1H),7.36(d,J=8.3Hz,1H),7.24(t,J=7.7Hz,1H),5.91(s,1H),5.17(s,2H),5. 02(s,1H),4.55(s,2H),3.65–3.49(m,4H),3.10(t,J=6.0Hz,1H),2.07–1.96(m,1H),1.81(s,3H),1.75–1.63(m,1H),1.40–1.15(m,2H). 13 C NMR (100 MHz, DMSO-d 6)δ161.85,161.47,156.93,152.72,146.70,139.21,131.08,124.25,122.39,117.94,116.79,11 6.16,80.72,80.38,75.34,59.50,51.10,49.79,40.99,38.28,34.17,3.62.HRMS(ESI)m / z:calcd for C 22 H 24 N 5 O 3 + [M+H] + ;406.1879,found:406.1883.
[0104] Example 27: Preparation of (R)-1-(but-2-yn-1-yl)-6-(3-hydroxypyrrolidin-1-yl)-3-((2-oxo-1,2-dihydroquinolin-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10b).
[0105] Using intermediate 3r and (R)-1-bromopyrrolidin-3-ol as raw materials, the synthesis method was the same as compound 10a, and the product 10b was collected as a white solid with a yield of 58% and a purity of 95.00%. 1 H NMR (400 MHz, Chloroform-d 6 )δ11.65(s,1H),7.79(d,J=9.5Hz,1H),7.49(t,J=8.3Hz,1H),7.35(d,J=9.4Hz,1 H),7.28–7.23(m,1H),6.33(s,1H),5.41(s,2H),5.20(s,1H),4.60(dt,J=16.0,2 .3Hz,2H),3.75(td,J=9.4,7.1Hz,1H),3.59(dd,J=10.9,4.3Hz,1H),3.50–3.41( m,2H),2.98(s,1H),2.14–2.10(m,1H),1.82(t,J=2.3Hz,3H),1.40–1.24(m,2H). 13 C NMR (100 MHz, DMSO-d 6)δ161.83,161.48,156.96,152.70,146.66,139.24,131.06,124.25,122.37,117.96,116.86,11 6.17,80.96,80.42,75.31,69.34,59.60,49.27,49.07,38.27,33.73,3.59.HRMS(ESI)m / z:calcd forC 22 H 23 N 4 O 4 + [M+H] + :407.1719,found:407.1716.
[0106] Example 28: Preparation of (R)-1-(but-2-yn-1-yl)-6-(3-hydroxypiperidin-1-yl)-3-((2-oxo-1,2-dihydroquinolin-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10c).
[0107] Using intermediate 3r and (R)-1-bromopiperidin-3-ol as raw materials, the synthesis method was the same as compound 10a, and the product 10c was collected as a white solid with a yield of 56% and a purity of 95.00%. 1 H NMR (400 MHz, Chloroform-d 6 )δ12.15(s,1H),7.77(d,J=8.2Hz,1H),7.49(t,J=7.7Hz,1H),7.37(d,J=8.2Hz,1H), 7.27–7.21(m,1H),6.31(s,1H),5.40(s,2H),5.35(s,1H),4.62(p,J=2.5Hz,2H),4.02 –3.91(m,1H),3.31–3.21(m,1H),3.14(d,J=11.8Hz,1H),3.06–2.95(m,2H),1.96(t, J=10.1Hz,1H),1.82(t,J=2.3Hz,3H),1.68(q,J=10.2,9.7Hz,2H),1.39–1.26(m,2H). 13 C NMR (100 MHz, DMSO-d 6)δ162.08,161.82,160.20,152.15,146.26,139.21,131.11,124.24,122.40,117.88,116.73,116.1 7,87.73,80.22,75.01,65.11,57.61,51.04,41.20,36.37,32.63,22.35,3.57.HRMS(ESI)m / z:calcd for C 23 H 25 N 4 O 4 + [M+H] + :421.1876,found:421.1879.
[0108] Example 29: Preparation of (R)-6-(3-aminoazacycl-1-yl)-3-(benzo[d]thiazol-2-ylmethyl)-1-(but-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione (10d).
[0109] Using intermediate 3p and (R)-1-bromoazacyclo-3-amine as raw materials, the synthesis method was the same as compound 10a, and the product 10d was collected as a white solid with a yield of 32% and a purity of 95.21%. 1 H NMR (400 MHz, Chloroform-d 6 )δ8.02(d,J=8.1Hz,1H),7.83(d,J=7.6Hz,1H),7.45(ddd,J=8.3,7.2,1.3Hz,1H),7.36(ddd,J=8.3, 7.2,1.3Hz,1H),5.55(d,J=1.5Hz,2H),5.39(s,1H),4.62(qq,J=17.0,2.3Hz,2H),3.43(dd,J=13.7,3 .7Hz,1H),3.27–3.21(m,2H),3.00(dd,J=13.7,8.2Hz,1H),2.06–1.97(m,1H),1.96–1.87(m,1H),1. 83(t,J=2.4Hz,3H),1.62(t,J=4.3Hz,3H),1.56–1.49(m,1H),1.39(s,1H),1.30(s,1H),1.27(s,1H). 13 C NMR (100 MHz, DMSO-d 6)δ167.91,161.74,161.37,152.72,152.31,135.07,126.68,125.68,122.95,122.68,87.81,80 .09,75.00,61.25,54.52,51.36,42.79,37.12,36.68,27.93,22.86,3.56.HRMS(ESI)m / z:calcd forC 22 H 26 N 5 O 2 S + [M+H] + :424.1807,found:424.1812.
[0110] Example 30: Preparation of (R)-6-(3-aminopyrrolidin-1-yl)-3-(benzo[d]thiazol-2-ylmethyl)-1-(but-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione (10e).
[0111] Using intermediate 3p and (R)-1-bromopyrrolidin-3-amine as raw materials, the synthesis method was the same as compound 10a, and the product 10e was collected as a white solid with a yield of 40% and a purity of 95.40%. 1 H NMR (400 MHz, Chloroform-d 6 )δ8.01(d,J=8.8Hz,1H),7.81(d,J=9.4Hz,1H),7.44(ddd,J=8.3,7.2,1.3Hz,1H),7.34(ddd,J =7.7,7.3,1.3Hz,1H),5.54(s,2H),5.16(s,1H),4.57(q,J=2.1Hz,2H),3.76–3.69(m,1H),3.6 3(dt,J=9.9,7.1Hz,1H),3.55(dd,J=10.0,5.6Hz,1H),3.47–3.38(m,1H),3.13(dd,J=10.0,4. 5Hz, 1H), 2.18 (dq, J=13.0, 6.7Hz, 1H), 1.82 (t, J=2.3Hz, 3H), 1.77 (s, 2H), 1.38–1.27 (m, 1H). 13 C NMR (100 MHz, Chloroform-d 6)δ166.93,161.91,156.59,152.89,152.50,135.39,125.84,124.99,123.23,121.46,82 .77,80.64,73.62,59.53,50.85,49.74,42.72,37.78,34.44,3.69.HRMS(ESI)m / z:calcd for C 20 H 22 N 5 O 2 S + [M+H] + :396.1494,found:396.1505.
[0112] Example 31: Preparation of (R)-3-(benzo[d]thiazol-2-ylmethyl)-1-(but-2-yn-1-yl)-6-(3-hydroxypiperidin-1-yl)pyrimidine-2,4(1H,3H)-dione (10f).
[0113] Using intermediate 3p and (R)-1-bromopiperidin-3-ol as raw materials, the synthesis method was the same as compound 10a, and the product 10f was collected as a white solid with a yield of 58% and a purity of 98.87%. 1 H NMR (400 MHz, Chloroform-d 6 )δ8.01(d,J=8.2Hz,1H),7.82(d,J=8.4Hz,1H),7.44(ddd,J=8.3,7.2,1.3Hz,1H),7.35 (ddd,J=8.2,7.2,1.2Hz,1H),5.54(s,2H),5.33(s,1H),4.62(qq,J=16.9,2.3Hz,2H),4 .01–3.94(m,1H),3.25–3.18(m,1H),3.05(d,J=8.0Hz,1H),3.00(d,J=7.1Hz,1H),2.51 (s,1H),1.98–1.90(m,2H),1.82(t,J=2.3Hz,3H),1.73–1.62(m,2H),1.40–1.22(m,1H). 13 C NMR (100 MHz, Chloroform-d 6)δ166.36,162.27,159.85,152.82,152.03,135.35,125.93,125.11,123.25,121.48,89.39 ,80.69,73.65,65.72,57.44,51.77,42.77,35.68,31.78,21.61,3.62.HRMS(ESI)m / z:calcd for C 21 H 23 N 4 O 3 S + [M+H] + :411.1491,found:411.1499.
[0114] Example 32: The fluorescence reporter strain method was used to determine the lasB inhibition rate of the derivatives against Pseudomonas aeruginosa PAO1.
[0115] Experimental method: The reporter strain was cultured overnight in LB medium and diluted with ABTGC medium to OD 600 The concentration of 0.02 was added to a 96-well plate, so that each well contained 75 μL of culture medium and 75 μL of bacterial solution containing the compound. A DMSO group (0.1% DMSO) and a blank group (culture medium only) were set up at the same time. The plate was then placed in an ELISA reader and incubated at 37°C, and GFP fluorescence (excitation wavelength 485 nm, emission wavelength 535 nm) was measured every 15 min for at least 12 hours.
[0116] Table 2 Inhibition rate of uracil derivatives against Pseudomonas aeruginosa PAO1-lasB-gfp fluorescent reporter strain
[0117]
[0118] a Data are shown as mean ± SD. All experiments were performed three times.
[0119] Experimental results: As shown in Table 2, uracil derivatives all showed good lasB inhibitory activity. The inhibition rates of compounds 4d, 4h, 9b, 9c, 9d, 9f, 9k, 9m, 10c, 10d, 10e, and 10f on lasB all reached more than 50%. Among them, compound 10e had the highest lasB inhibition rate of 54.74%, which was the most active compound and had the potential to be used as an anti-virulence compound to treat Pseudomonas aeruginosa infection.
[0120] Example 48: Study on the antibacterial synergistic effect of compound 10e on ciprofloxacin (CIP) and tobramycin (Tob) in a mouse wound infection model
[0121] Experimental methods: This animal experiment was conducted in accordance with the relevant national regulations on animal experiments. Pseudomonas aeruginosa PAO1 strain was used in this animal experiment. Female mice (5 weeks old, Babl / c) were purchased from SPF (Beijing) Biotechnology.co. Ltd. During the entire experimental process, mice were provided with sufficient food and water, and the living environment was maintained at 26°C and a 12-h light / night cycle. First, the mice were anesthetized with 4% chloral hydrate on day 0. A 4-5 mm circular wound was established on the back of each shaved mouse, and 5×10 8 CFU of PAO1. 24 hours after infection, different groups of mice were treated with different drugs (normal saline, 0.002mg / ml CIP, 0.002mg / ml CIP+2.5μM 10e, 0.0025mg / ml Tob, 0.0025mg / ml Tob+2.5μM 10e). After 3 consecutive days of administration, the infected skin of the mouse wound was homogenized and analyzed for CFU counting. After continuous observation of the wound for 9 days, the heart, liver, spleen, lung, and kidney of the mouse were removed for H&E staining.
[0122] Experimental results: The results show that ( Figure 1 and 2 ) Compared with the untreated control or wounds treated with 2.5μM 10e, the bacterial count in the wounds was greatly reduced after 0.002mg / ml CIP, 0.0025mg / ml Tob and 2.5μM 10e were combined, and were better than the group with antibiotics alone. At the same time, similar results were obtained by monitoring the wound area of mice. The healing rate of the wounds in the combined drug group was accelerated, proving that 10e has a good antibacterial synergistic effect on CIP and ciprofloxacin. In addition, the H&E staining results of mouse lung tissue sections showed that the combination of 10e and CIP or Tob had no obvious toxicity to mice.
[0123] The above embodiments are only used to help understand the method and core idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. A compound represented by formula (I) or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof:
2. The compound of formula (1) according to claim 1 or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof, Features Has the chemical structure shown below:
3. A pharmaceutical composition, It is characterized in that It comprises the compound represented by formula (I) as claimed in claim 1, or at least one of its pharmaceutically acceptable salts, isomers, solvates or prodrugs, and optionally a pharmaceutically acceptable excipient or carrier.
4. A combination drug comprising at least one of the compound represented by formula (I) or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof, and an antibiotic.
5. The combination drug according to claim 4, wherein the antibiotics include ciprofloxacin and tobramycin; the mass ratio of the compound represented by formula (I) or its pharmaceutically acceptable salt, isomer, solvate or prodrug to the antibiotic is 1:0.5-10, preferably 1:2-3, and more preferably 1:2-2.
5.
6. Use of the compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt, isomer, solvate or prodrug thereof in the preparation of a lasB inhibitor.
7. Use of the compound of formula (I) according to claim 1 or its pharmaceutically acceptable salt, isomer, solvate or prodrug in the preparation of antibacterial drugs.
8. The use according to claim 7, wherein the bacteria is a bacterium, preferably Pseudomonas aeruginosa.
9. A method for preparing the compound of formula (I) as claimed in claim 2, comprising any one of the following routes: Route 1, The following steps are involved: (1.1) The raw material 6-chlorouracil 1 reacts with 1-bromo-2-butyne to obtain intermediate 2; (1.2) Intermediate 2 is reacted with a bromine-substituted compound through alkylation to give intermediates 3a-3l; (1.3) Intermediates 3a-3l react with (R)-3-aminopiperidine dihydrochloride to give final products 4a-4l; The synthetic route at this time is: Route 2 includes the following steps: (2.1) Intermediate 2 reacts with methyl 3-(bromomethyl)benzoate to generate intermediate 4; (2.2) Intermediate 4 reacts with (R)-3-Boc-aminopiperidine to give intermediate 5; (2.3) Intermediate 5 is further hydrolyzed to obtain intermediate 6; (2.4) Intermediate 6 is reacted with different amino-substituted compounds 7a-7m to give intermediates 8a-8m; (2.5) The intermediate 8a-8m is hydrolyzed to remove the Boc protecting group to obtain the target product 9a-9m; Route 3 includes the following steps: (3.1) Add intermediate 2 to DMF solution, add sodium hydride and lithium bromide under ice bath condition, stir, add bromine-substituted compound to the reaction solution, and react at room temperature overnight; post-treatment: add water to the reaction solution to terminate the reaction, extract with ethyl acetate, combine the organic phases, wash with water, dry with anhydrous sodium sulfate, and purify by silica gel column chromatography to obtain intermediates 3r and 3p; (3.2) Add intermediate 3r or 3p, substituted amine, sodium bicarbonate and activated molecular sieve (4A) to the ethanol solution, respectively, and react at 100°C for 2.5 hours; post-treatment: concentrate the reaction and purify by silica gel column chromatography to obtain the final products 10a-10f;
Citation Information
Patent Citations
Preparation method of high-efficient DPP (dipeptidyl peptidase)-IV inhibitor
CN103044392A
Uracil derivatives containing benzene carboxylic acid or benzamide and preparation method and medical application thereof
CN111116549A
Coumarin derivative as well as preparation method and application thereof
CN116621801A
